ROLIPRAM AND PDE4 INHIBITION AS PROMISING THERAPEUTICS IN INFLAMMATION

Authors

  • E. Mammadov Ege Hospital, Baku, Azerbaijan
  • S. İmamverdiyev Azerbaijan Medical University, Baku, Azerbaijan
  • R. Naghiyev Azerbaijan Medical University, Baku, Azerbaijan
  • O. Isayev Azerbaijan Medical University, Baku, Azerbaijan

DOI:

https://doi.org/10.46827/ejphs.v8i3.225

Keywords:

reactive oxygen species, ischemia–reperfusion injury, inflammation, rolipram

Abstract

Ischemia-reperfusion injury (IRI) remains a significant clinical challenge due to the complexity of its pathophysiology, which encompasses oxidative stress, inflammation, and regulated cell death. The evidence reviewed in this study highlights the promising role of Rolipram as a potential therapeutic agent for mitigating ischemia-reperfusion (I/R)-induced tissue damage. By increasing intracellular cAMP levels, Rolipram modulates key molecular pathways, including NF-κB, MAPK, and CREB, leading to a reduction in pro-inflammatory cytokine production, an inhibition of oxidative stress, and an enhancement of cellular survival mechanisms. Future research should aim to address these limitations through the use of advanced delivery systems, isoform-selective inhibitors, and well-controlled clinical trials. Nevertheless, the current evidence base supports the ongoing investigation of Rolipram as a multifunctional therapeutic candidate with the potential to significantly improve outcomes in ischemia-reperfusion injury.

 

Author Biographies

  • E. Mammadov, Ege Hospital, Baku, Azerbaijan

    Dr. Emin Məmmədov is a urologist-andrologist, with medical training from Azerbaijan Medical University and specialist certification from Çukurova University in Adana, Turkey. He also holds the prestigious European Board of Urology (FEBU) diploma and specializes in advanced urological surgery.

  • S. İmamverdiyev, Azerbaijan Medical University, Baku, Azerbaijan

    Professor Sudeyif B. İmamverdiyev is an esteemed urologist-scientist at Azerbaijan Medical University, where he established the university's Urology Hospital in 1975 and has led the Urology Department since 1990. He is a corresponding member of the Azerbaijan National Academy of Sciences and the accomplished author of numerous innovations and rationalization proposals in surgical methodology.

  • R. Naghiyev, Azerbaijan Medical University, Baku, Azerbaijan

    Dr. Rauf N. Naghiyev is an Associate Professor (Teaching Assistant) in the Department of Urology at Azerbaijan Medical University, specializing in laparoscopic nephrectomy and other minimally invasive urological surgeries. He has co-authored peer-reviewed studies assessing outcomes of laparoscopic partial and radical nephrectomies, contributing to the advancement of urological surgical practices.

  • O. Isayev, Azerbaijan Medical University, Baku, Azerbaijan

    Associate Professor Orxan Isayev is a medical doctor specializing in histology, embryology, and cytology at Azerbaijan Medical University. Educated at AMU (2005–2011) and later trained in oncology research during his doctoral studies at Heidelberg University (2012–2014), he has co-authored multiple peer-reviewed studies on cancer stem cells and pancreatic cancer mechanisms.

References

Ali, M., Pham, A., Wang, X., Wolfram, J., Pham, S. (2020). Extracellular vesicles for treatment of solid organ ischemia–reperfusion injury. Am J Transplant. 2020;20(12):3294-3307. https://doi.org/10.1111/ajt.16164

Bhatt, S., Singh, A. P., & Kumar, S. (2024). Phosphodiesterase Inhibitors: A Therapeutic Approach for Arsenic-Induced Neurotoxicity. Drug Metabolism and Bioanalysis Letters, 17(2), 67-75. https://doi.org/10.2174/0118723128343703250103063848

Bozkurt, A., Karakoy, Z., Aydin, P., Ozdemir, B., Toktay, E., Halici, Z., & Cadirci, E. (2024). Targeting Aquaporin-5 by Phosphodiesterase 4 Inhibition Offers New Therapeutic Opportunities for Ovarian Ischemia Reperfusion Injury in Rats. Reproductive Sciences, 31(7), 2021-2031. https://doi.org/10.1007/s43032-024-01496-w

Cai, J., Chen, X., Liu, X., Li, Z., Shi, A., Tang, X., ... & Yu, P. (2022). AMPK: The key to ischemia‐reperfusion injury. Journal of cellular physiology, 237(11), 4079-4096. https://doi.org/10.1002/jcp.30875

Fan, T., Wang, W., Wang, Y., Zeng, M., Liu, Y., Zhu, S., & Yang, L. (2024). PDE4 inhibitors: potential protective effects in inflammation and vascular diseases. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1407871

Güler, M. C., Tanyeli, A., Akdemir, F. N. E., Eraslan, E., Şebin, S. Ö., Erdoğan, D. G., & Nacar, T. (2022). An Overview of Ischemia–Reperfusion Injury: Review on Oxidative Stress and Inflammatory Response. The Eurasian Journal of Medicine, 54(Suppl 1), S62. https://doi.org/10.5152/eurasianjmed.2022.22293

Kvietys, PR., Granger, DN. (2012). Role of reactive oxygen and nitrogen species in the vascular responses to inflammation. Free Radic Biol Med. 2012;52(3):556- 592

Lu, X., Wang, J., Chen, X., Jiang, Y., & Pan, Z. K. (2020). Rolipram protects mice from gram-negative bacterium Escherichia coli-induced inflammation and septic shock. Scientific Reports, 10(1), 175. Retrieved from https://doi.org/10.1016/j.freeradbiomed.2011.11.002

Ma, J., Staler, D. W., & Mahato, R. I. (2024). Targeting cAMP signaling and phosphodiesterase 4 for liver disease treatment. Medicinal Chemistry Research, 33(8), 1339-1353. Retrieved from https://link.springer.com/article/10.1007/s00044-024-03267-3

Maher, A., El Sayed, N., Nafea, H., & Gad, M. (2022). Rolipram rescues memory consolidation deficits caused by sleep deprivation: Implication of the cAMP/PKA and cAMP/Epac pathways. CNS & Neurological Disorders-Drug Targets-CNS & Neurological Disorders), 21(7), 631-639. Retrieved from https://doi.org/10.2174/1871527320666210816105144

Nashtahosseini, Z., Eslami, M., Paraandavaji, E., Haraj, A., Dowlat, B. F., Hosseinzadeh, E., ... & Naderian, R. (2025). Cytokine Signaling in Diabetic Neuropathy: A Key Player in Peripheral Nerve Damage. Biomedicines, 13(3), 589. https://doi.org/10.3390/biomedicines13030589

Pomarede, N., Chandramouli, M. (2009). Enhancing the skin's natural antioxidant enzyme system by the supplementation or upregulation of superoxide dismutase, catalase, and glutathione peroxidase. Nutr Cosmet. 2009:245-265. Retrieved from https://doi.org/10.1016/B978-0-8155-2029-0.50020-X

Schneider, L., Jabrailova, B., Salem, M., Kilk, K., Hofer, S., Brenner, T., ... & Werner, J. (2016). Stimulation of central α2 receptors attenuates experimental necrotizing pancreatitis. Pancreas, 45(2), 260-264. Retrieved from https://doi.org/10.1097/mpa.0000000000000474

Schneider, L., Jabrailova, B., Soliman, H., Hofer, S., Strobel, O., Hackert, T., ... & Werner, J. (2014). Pharmacological cholinergic stimulation as a therapeutic tool in experimental necrotizing pancreatitis. Pancreas, 43(1), 41-46. https://doi.org/10.1097/mpa.0b013e3182a85c21

Schneider, L., Jabrailova, B., Strobel, O., Hackert, T., & Werner, J. (2015). Inflammatory profiling of early experimental necrotizing pancreatitis. Life Sciences, 126, 76-80. https://doi.org/10.1016/j.lfs.2015.01.029

Tang, J., Zhuang, S. (2019). Histone acetylation and DNA methylation in ischemia/reperfusion injury. Clin Sci (Lond). 2019;133(4):597-609. https://doi.org/10.1042/cs20180465

Tanyeli, A., Nur, F., Akdemir, E. (2022). The possible useful effectiveness of sinapic acid sepsis-induced secondary organ damage in rats. Clin Exp Health Sci. 2022;12(1):134-140. http://dx.doi.org/10.33808/clinexphealthsci.864015

Varona, S., Puertas, L., Galán, M., Orriols, M., Cañes, L., Aguiló, S., ... & Rodríguez, C. (2021). Rolipram prevents the formation of abdominal aortic aneurysm (AAA) in mice: PDE4B as a target in AAA. Antioxidants, 10(3), 460. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8000788/

Zhang, M., Liu, Q., Meng, H., Duan, H., Liu, X., Wu, J., ... & Yuan, J. (2024). Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets. Signal transduction and targeted therapy, 9(1), 12. Retrieved from https://doi.org/10.1038/s41392-023-01688-x

Zhong, J., Yu, X., & Lin, Z. (2025). Phosphodiesterase 4 inhibition as a novel treatment for stroke. PeerJ, 13, e18905. https://doi.org/10.7717/peerj.18905

Downloads

Published

2025-08-12

Issue

Vol. 8 No. 3 (2025)

Section

Articles

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

How to Cite

ROLIPRAM AND PDE4 INHIBITION AS PROMISING THERAPEUTICS IN INFLAMMATION. (2025). European Journal of Public Health Studies, 8(3). https://doi.org/10.46827/ejphs.v8i3.225